Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor

Diabetes

Volumn 55, Issue 5, 2006, Pages 1484-1490

  Cani, Patrice D ^a,b   Knauf, Claude ^a   Iglesias, Miguel A ^a   Drucker, Daniel J ^c   Delzenne, Nathalie M ^b   Burcelin, Rémy ^a,d  

^a CNRS   (France)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHU RANGUEIL   (France)

Author keywords

ELISA, enzyme linked immunosorbent assay; GLP 1, glucagon like peptide 1; IKK, inhibitor of B kinase; IRS, insulin receptor substrate; NF B, nuclear factor B; OFS, oligofructose

Indexed keywords

EXENDIN 9; FRUCTOSE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 2; OLIGOFRUCTOSE; PANCREAS HORMONE; PROGLUCAGON; PROTEIN KINASE B; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; INSULIN; MESSENGER RNA; OLIGOSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENERGY CONSUMPTION; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WEIGHT CHANGE; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DIET RESTRICTION; DRUG EFFECT; EPIDIDYMIS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE TOLERANCE TEST; HISTOLOGY; METABOLISM; MOUSE MUTANT; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; EPIDIDYMIS; FASTING; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOSACCHARIDES; PROGLUCAGON; RECEPTORS, GLUCAGON; RNA, MESSENGER;

EID: 33745126131     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1360     Document Type: Article

References (44)

1. Parillo M, Riccardi G: Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence. Br J Nutr 92:7-19, 2004
2. Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 (Suppl. 3):14-23, 2002
3. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B: Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282:E834-E842, 2002
4. Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 27 (Suppl. 3):S6-S11, 2003
5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003
6. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW: The role of intramuscular lipid in insulin resistance. Acta Physiol Scand 178:373-383, 2003
7. Bonner G: Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol 24 (Suppl. 2):S39-S49, 1994
8. Koopmans SJ, Ohman L, Haywood JR, Mandarino LJ, DeFronzo RA: Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism but not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats. Diabetes 46:1572-1578, 1997
9. Yki-Jarvinen H: Fat in the liver and insulin resistance. Ann Med 37:347-356, 2005
10. Raz I, Eldor R, Cernea S, Shafrir E: Diabetes: insulin resistance and derangements in lipid metabolism: cure through intervention in fat transport and storage. Diabetes Metab Res Rev 21:3-14, 2005
11. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206, 2004
12. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
13. Delzenne NM, Williams CM: Prebiotics and lipid metabolism. Curr Opin Lipidol 13:61-67, 2002
14. Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC, Galmiche JP: Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 124:894-902, 2003
15. Cani PD, Joly E, Horsmans Y, Delzenne NM: Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2005 [Epub ahead of print]
16. Yamashita K, Itakura M, Kawai K: Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetics subjects. Nutr Res 4:961-966, 1984
17. Cani PD, Neyrinck AM, Maton N, Delzenne NM: Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. Obes Res 13:1000-1007, 2005
18. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM: Involvement of endogenous glucagonlike peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 185:457-465, 2005
19. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258, 1996
20. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury J, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti J, Delzenne NM, Postic C, Burcelin R: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 112:3554-3563, 2005
21. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cellspecific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315, 1999
22. Defronzo R, Simonson D, Ferannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (noninsulin-dedendent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-319, 1982
23. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
24. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190, 2005
25. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191-198, 2005
26. Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Bruning JC: Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest 113:474-481, 2004
27. Scrocchi LA, Drucker DJ: Effects of aging and a high fat diet on body weight and glucose tolerance in glucagonlike peptide-1 receptor(-/-) mice. Endocrinology 139:3127-3132, 1998
28. Flamez D, Van Breusegem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ, Schuit F: Mouse pancreatic β-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 47:646-652, 1998
29. -/- mice. Diabetes 47:1046-1052, 1998
30. Vella A, Rizza RA: Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 36:830-836, 2004
31. Burcelin R: The incretins: a link between nutrients and well-being. Br J Nutr 93 (Suppl. 1):S147-S156, 2005
32. Ahren B: Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286:R269-R272, 2004
33. Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728, 2001
34. Ionut V, Hucking K, Liberty IF, Bergman RN: Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48:967-975, 2005
35. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD: Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287:E75-E81, 2004
36. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, Lautz M, Cherrington AD: Insulin secretion-independent effects of glucagon-like peptide 1 (GLP-1) on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 289:G806-G814, 2005
37. Balkan B, Li X: Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279:R1449-R1454, 2000
38. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A: Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271:E808-E813, 1996
39. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998
40. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
41. Van Dijk G, Lindskog S, Holst JJ, Steffens AB, Ahren B: Effects of glucagon-like peptide-I on glucose turnover in rats. Am J Physiol 270:E1015-E1021, 1996
42. Rodriquez, dF, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E: Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709-717, 2000
43. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR: Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250, 1999
44. Neyrinck AM, Alexiou H, Delzenne NM: Kupffer cell activity is involved in the hepatoprotective effect of dietary oligofructose in rats with endotoxic shock. J Nutr 134:1124-1129, 2004